dc.contributor.author | Halvorsen, Tarje Onsøien | |
dc.contributor.author | Sundstrøm, Stein Harald | |
dc.contributor.author | Fløtten, Øystein | |
dc.contributor.author | Brustugun, Odd Terje | |
dc.contributor.author | Brunsvig, Paal Fr. | |
dc.contributor.author | Aasebø, Ulf | |
dc.contributor.author | Bremnes, Roy M. | |
dc.contributor.author | Kaasa, Stein | |
dc.contributor.author | Grønberg, Bjørn Henning | |
dc.date.accessioned | 2017-11-15T08:09:47Z | |
dc.date.available | 2017-11-15T08:09:47Z | |
dc.date.created | 2016-11-18T13:00:34Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Acta Oncologica. 2016, 55 (11), 1349-1354. | nb_NO |
dc.identifier.issn | 0284-186X | |
dc.identifier.uri | http://hdl.handle.net/11250/2466308 | |
dc.description.abstract | Background: Many patients with limited disease small cell lung cancer (LD SCLC) suffer from comorbidity. Not all patients with comorbidity are offered standard treatment, though there is little evidence for such a policy. The aim of this study was to investigate whether patients with comorbidity had inferior outcomes in a LD SCLC cohort.
Material and methods: We analyzed patients from a randomized study comparing two three-week schedules of thoracic radiotherapy (TRT) plus standard chemotherapy in LD SCLC. Patients were to receive four courses of cisplatin/etoposide and TRT of 45 Gy/30 fractions (twice daily) or 42 Gy/15 fractions (once daily). Responders received prophylactic cranial irradiation (PCI). Comorbidity was assessed using the Charlson Comorbidity Index (CCI), which rates conditions with increased one-year mortality.
Results: In total 157 patients were enrolled between May 2005 and January 2011. Median age was 63 years, 52% were men, 16% had performance status 2, and 72% stage III disease. Forty percent had no comorbidity; 34% had CCI-score 1; 15% CCI 2; and 11% CCI 3–5. There were no significant differences in completion rates of chemotherapy, TRT or PCI across CCI-scores; or any significant differences in the frequency of grade 3–5 toxicity (p = 0.49), treatment-related deaths (p = 0.36), response rates (p = 0.20), progression-free survival (p = 0.18) or overall survival (p = 0.09) between the CCI categories.
Conclusion: Patients with comorbidity completed and tolerated chemo-radiotherapy as well as other patients. There were no significant differences in response rates, progression-free survival or overall survival – suggesting that comorbidity alone is not a reason to withhold standard therapy in LD SCLC. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | Taylor & Francis | nb_NO |
dc.title | Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | acceptedVersion | nb_NO |
dc.source.pagenumber | 1349-1354 | nb_NO |
dc.source.volume | 55 | nb_NO |
dc.source.journal | Acta Oncologica | nb_NO |
dc.source.issue | 11 | nb_NO |
dc.identifier.doi | 10.1080/0284186X.2016.1201216 | |
dc.identifier.cristin | 1401776 | |
dc.description.localcode | This is an [Accepted Manuscript] of an article published by Taylor & Francis in [Acta Oncologica] on [23 Aug 2016], available at http://www.tandfonline.com/doi/full/10.1080/0284186X.2016.1201216 | nb_NO |
cristin.unitcode | 194,65,15,0 | |
cristin.unitname | Institutt for klinisk og molekylær medisin | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.fulltext | postprint | |
cristin.qualitycode | 1 | |